Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation

Atherosclerosis

Volumn 236, Issue 1, 2014, Pages 108-115

  Clancy, Paula ^a   Koblar, Simon A ^b   Golledge, Jonathan ^a,c  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c TOWNSVILLE HOSPITAL   (Australia)

Author keywords

Angiotensin II; Angiotensin receptor blocker; Anti Inflammatory; Atheroma; Cytokine; Extracellular signal regulated kinase

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; CXCL2 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERLEUKIN 6; INTERLEUKIN 8; IRBESARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOPONTIN; OSTEOPROTEGERIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; BIPHENYL DERIVATIVE; CHEMOKINE; CYTOKINE; DX600 PEPTIDE; MAPK1 PROTEIN, HUMAN; PEPTIDE; TETRAZOLE DERIVATIVE; TNFRSF11B PROTEIN, HUMAN;

ARTICLE; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG DOSE TITRATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; IN VITRO STUDY; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; AGED; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; DRUG EFFECTS; ENZYME INDUCTION; ENZYMOLOGY; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECRETION (PROCESS); SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

1-SARCOSINE-8-ISOLEUCINE ANGIOTENSIN II; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; CAROTID ARTERIES; CELLS, CULTURED; CHEMOKINES; CYTOKINES; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; ENZYME INDUCTION; FEMALE; HUMANS; INFLAMMATION; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OSTEOPROTEGERIN; PEPTIDES; PLAQUE, ATHEROSCLEROTIC; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 84905843088     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.06.011     Document Type: Article

References (44)

1. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
2. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomised double-blind intervention trial. J Hypertens 2003, 21:875-886.
3. Schrader J., Luders S., Kulschewski A., Hammersen F., Plate K., Berger J., et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomised controlled study (MOSES). Stroke 2005, 36:1218-1224.
4. Di Raimondo D., Tuttolomondo A., Buttà C., Miceli S., Licata G., Pinto A. Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. Curr Pharm Des 2012, 18:4385-4413.
5. Takagi H., Mizuno Y., Yamamoto H., Goto S.N., Umemoto T. Effects of telmisartan therapy on interleukin-6 and tumour necrosis factor-alpha levels: a meta-analysis of randomised controlled trials. Hypertens Res 2013, 36:368-373.
6. Xie Q.Y., Wang Y.J., Sun Z.L., Yang T.L. Effects of valsartan and indapamide on plasma cytokines in essential hypertension. J Cent South Univ Med Sci 2006, 31:629-634.
7. Ceriello A., Assaloni R., Da Ros R., Maier A., Piconi L., Quagliaro L., et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005, 111:2518-2524.
8. Tsutamoto T., Wada A., Maeda K., Mabuchi N., Hayashi M., Tsutsui T., et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000, 35:714-721.
9. Manabe S., Okura T., Watanabe S., Fukuoka T., Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005, 46:735-739.
10. Martinez-Martin F.J., Rodriguez-Rosas H., Peiro-Martinez I., Soriano-Perera P., Pedrianes-Martin P., Comi-Diaz C. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens 2011, 25:346-353.
11. Fliser D., Buchholz K., Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004, 110:1103-1107. EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators.
12. Koh K.K., Ahn J.Y., Choi Y.M., Han S.H., Kim D.S., Kim H.S., et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003, 42:905-910.
13. Koh K.K., Quon M.J., Han S.H., ChungJ W.J., Ahn J.Y., Seo Y.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110:3687-3692.
14. Kurata M., Okura T., Irita J., Enomoto D., Nagao T., Jotoku M., et al. Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension. J Hum Hypertens 2011, 25:334-339.
15. Lorenzen J.M., Neunhöffer H., David S., Kielstein J.T., Haller H., Fliser D. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension-results from the EUTOPIA trial. Atherosclerosis 2010, 209:184-188.
16. Mehta P.K., Griendling K.K. Angiotensin II cell signalling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007, 292:C82-C97.
17. Roux P.P., Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004, 68:320-344.
18. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005, 1754:253-262.
19. Clancy P., Koblar S.A., Golledge J. Role of the angiotensin converting enzyme 1/angiotensin II/angiotensin receptor 1 axis in interstitial collagenase expression in human carotid atheroma. Atherosclerosis 2013, 29:331-337.
20. Golledge J., Mangan S., Clancy P. Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas. Stroke 2007, 38:1501-1508.
21. Mangan S., Clancy P., Golledge J. Modulation of endothelial cell thrombomodulin by PPAR ligands-variation according to environment. Thromb Res 2007, 121:827-834.
22. Clancy P, Lincz L, Maguire J, McEvoy M, Koblar S, Golledge J. Tenascin-C is increased in atherothrombotic stroke patients and has an anti-inflammatory effect in the human carotid artery. Biofactors. [published online May 14th, 2014].
23. Christen Y., Waeber B., Nussberger J., Porchet M., Borland R.M., Lee R.J., et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991, 83:1333-1342.
24. Seva Pessoa B., van der Lubbe N., Verdonk K., Roks A.J., Hoorn E.J., Danser A.H. Key developments in renin-angiotensin-aldosterone system inhibition. Nat Rev Nephrol 2013, 9:26-36.
25. Rao L.V., Pendurthi U.R. Tissue factor-factor VIIa signalling. Arterioscler Thromb Vasc Biol 2005, 25:47-56.
26. Thway T.M., Shlykov S.G., Day M.C., Sanborn B.M., Gilstrap L.C., Xia Y. Antibodies from preeclamptic patients stimulate increased intracellular ca2+ mobilisation through angiotensin receptor activation. Circulation 2004, 110:1612-1619.
27. Dragun D., Müller D.N., Bräsen J.H., Fritsche L., Nieminen-Kelhä M., Dechend R. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558-569.
28. Yatabe J., Sanada H., Yatabe M.S., Hashimoto S., Yoneda M., Felder R.A., et al. Angiotensin II type 1 receptor blocker attenuates the activation of ERK and NADPH oxidase by mechanical strain in mesangial cells in the absence of angiotensin II. Am J Physiol Renal Physiol 2009, 296:F1052-F1060.
29. Zou Y., Akazawa H., Qin Y., Sano M., Takano H., Minamino T., et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004, 6:499-506.
30. Chiu A.T., Peach M.J. Inhibition of induced aldosterone biosynthesis with a specific antagonist of angiotensin II. Proc Natl Acad Sci U S A 1974, 71(2):341-344.
31. Goodfriend T.L., Peach M.J. Angiotensin III: (des-aspartic acid1)-angiotensin II evidence and speculation for its role as an important agonist in the renin angiotensin system. Circ Res 1975, 36(Suppl.):I-38-I-40.
32. Ray P.E., Aguilera G., Kopp J.B., Horikoshi S., Klotman P.E. Angiotensin II receptor-mediated proliferation of cultured human fetal mesangial cells. Kidney Int 1991, 40:764-771.
33. Ibrahim J., Hughes A.D., Sever P.S. Action of angiotensin II on DNA synthesis by human saphenous vein in organ culture. Hypertension 2000, 36:917-921.
34. Feener E.P., Northrup J.M., Aiello L.P., King G.L. Angiotensin II induces plasminogen activator inhibitor-1 and-2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995, 95:1353-1362.
35. Olson J.A., Shiverick K.T., Ogilvie S., Buhi W.C., Raizada M.K. Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Proc Natl Acad Sci U S A 1991, 88:1928-1932.
36. Bae S.K., Kim M.J., Shim E.J., Cho D.Y., Shon J.H., Liu K.H. HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies. Biomed Chromatogr 2009, 23:568-572.
37. Pool J.L., Guthrie R.M., Littlejohn T.W., Raskin P., Shephard A.M., Weber M.A. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998, 11:462-470.
38. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995, 270:27489-27494.
39. Peng N., Liu J.T., Gao D.F., Lin R., Li R. Angiotensin II-induced C-reactive protein generation: inflammatory role of vascular smooth muscle cells in atherosclerosis. Atherosclerosis 2007, 193:292-298.
40. Lo M.W., Goldberg M.R., McCrea J.B., Lu H., Furtek C.I., Bjornsson T.D. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995, 58:641-649.
41. Kazierad D.J., Martin D.E., Blum R.A., Tenero D.M., Ilson B., Boike S.C., et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997, 62:417-425.
42. Wang J.M., Wang Y., Zhu Z.S., Zhang M.C., Zou Y., Li J.J. Diverse effects of long-term treatment with imidapril and irbesartan on cell growth signal, apoptosis and collagen type I expression in the left ventricle of spontaneously hypertensive rats. Life Sci 2004, 75:407-420.
43. Bosnyak S., Jones E.S., Christopoulos A., Aguilar M.I., Thomas W.G., Widdop R.E. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci 2011, 121:297-303.
44. Le M.T., Vanderheyden P.M., Szaszák M., Hunyady L., Vauquelin G. Angiotensin IV is a potent agonist for constitutive active human AT1 receptors: distinct roles of the C-terminal residues of angiotensin II during AT1 receptor activation. J Biol Chem 2002, 277:23107-23111.